# Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

> **NCT00440726** · PHASE1,PHASE2 · COMPLETED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 31 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** PEG-asparaginase
- **DRUG:** Doxorubicin
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Vincristine
- **DRUG:** Triple IT Therapy

## Key facts

- **NCT ID:** NCT00440726
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-04
- **Primary completion:** 2011-02-26
- **Final completion:** 2011-02-26
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440726, "Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00440726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*